CRS is effectively reversed with IL-6 blockade, and the best studied treatment is the IL-6 receptor antagonist (Tocilizumab) (11, 12) IL-6 blockade with Tocilizumab does not appear to impact the effectiveness or persistence of CAR-T cells (69). Here, IL6 is linked to congenital rubella syndrome.